137 related articles for article (PubMed ID: 38316017)
21. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
23. Differential binding modes of the bromodomains of CREB-binding protein (CBP) and p300 with acetylated MyoD.
Wei L; Jamonnak N; Choy J; Wang Z; Zheng W
Biochem Biophys Res Commun; 2008 Apr; 368(2):279-84. PubMed ID: 18222173
[TBL] [Abstract][Full Text] [Related]
24. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
[TBL] [Abstract][Full Text] [Related]
25. Roles for the coactivators CBP and p300 and the APC/C E3 ubiquitin ligase in E1A-dependent cell transformation.
Turnell AS; Mymryk JS
Br J Cancer; 2006 Sep; 95(5):555-60. PubMed ID: 16880778
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-1β/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis.
Su B; Luo T; Zhu J; Fu J; Zhao X; Chen L; Zhang H; Ren Y; Yu L; Yang X; Wu M; Feng G; Li S; Chen Y; Wang H
Hepatology; 2015 Feb; 61(2):585-97. PubMed ID: 25294684
[TBL] [Abstract][Full Text] [Related]
27. CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
Bordonaro M; Lazarova DL
World J Gastroenterol; 2015 Jul; 21(27):8238-48. PubMed ID: 26217075
[TBL] [Abstract][Full Text] [Related]
28. The ability of E1A to rescue ras-induced premature senescence and confer transformation relies on inactivation of both p300/CBP and Rb family proteins.
Deng Q; Li Y; Tedesco D; Liao R; Fuhrmann G; Sun P
Cancer Res; 2005 Sep; 65(18):8298-307. PubMed ID: 16166306
[TBL] [Abstract][Full Text] [Related]
29. The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression.
Turnell AS; Stewart GS; Grand RJ; Rookes SM; Martin A; Yamano H; Elledge SJ; Gallimore PH
Nature; 2005 Dec; 438(7068):690-5. PubMed ID: 16319895
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening.
Tian X; Suarez D; Thomson D; Li W; King EA; LaFrance L; Boehm J; Barton L; Di Marco C; Martyr C; Thalji R; Medina J; Knight S; Heerding D; Gao E; Nartey E; Cecconie T; Nixon C; Zhang G; Berrodin TJ; Phelps C; Patel A; Bai X; Lind K; Prabhu N; Messer J; Zhu Z; Shewchuk L; Reid R; Graves AP; McHugh C; Mangatt B
J Med Chem; 2022 Nov; 65(21):14391-14408. PubMed ID: 36302181
[TBL] [Abstract][Full Text] [Related]
31. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
32. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
33. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP.
Lundblad JR; Kwok RP; Laurance ME; Harter ML; Goodman RH
Nature; 1995 Mar; 374(6517):85-8. PubMed ID: 7870179
[TBL] [Abstract][Full Text] [Related]
34. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
36. An essential role for p300/CBP in the cellular response to hypoxia.
Arany Z; Huang LE; Eckner R; Bhattacharya S; Jiang C; Goldberg MA; Bunn HF; Livingston DM
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):12969-73. PubMed ID: 8917528
[TBL] [Abstract][Full Text] [Related]
37. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
39. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
40. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
